Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Eli Lilly and : to Supply Bamlanivimab to Treat Covid-19 in Canada

11/24/2020 | 01:26pm EST

By Stephen Nakrosis

Eli Lilly Canada said Tuesday it signed an agreement with the Government of Canada to supply bamlanivimab to treat patients suffering from Covid-19.

The company said it will supply an initial 26,000 doses between December 2020 and February 2021 for US$32.5 million.

"Lilly is taking a data-driven approach to the worldwide allocation of bamlanivimab according to our guiding principles that prioritize countries according to their medical need," the company said, adding "Additional doses will be supplied to Canada on a monthly basis according to the medical need in Canada and the availability of supply."

Lilly said bamlanivimab received authorization to treat certain adult and pediatric patients 12 years of age or older with mild to moderate Covid-19 on November 20.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

11-24-20 1325ET

All news about ELI LILLY AND COMPANY
09:51aELI LILLY AND COMPANY : - Lilly Confirms Date and Conference Call for Fourth-Qua..
AQ
09:51aELI LILLY AND COMPANY : - Lilly Announces $30 Million Limited Partner Investment..
AQ
01/15ELI LILLY AND : Insider at Eli Lilly (LLY) Makes Significant Sale of Stock
MT
01/15ELI LILLY AND : Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 ..
PR
01/15ELI LILLY AND COMPANY : - Gabrielle Sulzberger Elected to Lilly Board of Directo..
AQ
01/15ELI LILLY AND : Lilly Invests $30 Million in Venture Fund for Underrepresented F..
DJ
01/15ELI LILLY AND : Invests $30 Million in Venture Capital Fund Targeting Early-Stag..
MT
01/14INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Eli Lilly
MT
01/14ELI LILLY & CO : Change in Directors or Principal Officers, Financial Statements..
AQ
01/14ELI LILLY AND : Gabrielle Sulzberger Elected to Lilly Board of Directors
PR
More news
Financials (USD)
Sales 2020 24 408 M - -
Net income 2020 5 802 M - -
Net Debt 2020 11 301 M - -
P/E ratio 2020 30,0x
Yield 2020 1,56%
Capitalization 173 B 173 B -
EV / Sales 2020 7,55x
EV / Sales 2021 6,63x
Nbr of Employees 33 625
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 181,58 $
Last Close Price 190,77 $
Spread / Highest target 19,0%
Spread / Average Target -4,82%
Spread / Lowest Target -37,1%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY12.99%172 949
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993